Skip to main content
Fig. 1 | Health Economics Review

Fig. 1

From: Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques

Fig. 1

Simplified diagram of Markov model. Note: Vd, bortezomib-dexamethasone; Rd, lenalidomide-dexamethasone; Kd, carfilzomib-dexamethasone; DVd, daratumumab-bortezomib-dexamethasone; SVd, selinexor-bortezomib-dexamethasone; PVd, pomalidomide-bortezomib-dexamethasone; PanVd, pomalidomide-bortezomib-dexamethasone; ERd, elotuzumab-lenalidomide-dexamethasone; DRd, daratumumab-lenalidomide-dexamethasone; KRd, carfilzomib-lenalidomide-dexamethasone; IxaRd, ixazomib-lenalidomide-dexamethasone; Kd, carfilzomib-dexamethasone; DKd, daratumumab-carfilzomib-dexamethasone; IsaKd, isatuximab-carfilzomib-dexamethasone

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us